Molecular Analysis for Therapy Choice (MATCH)
Closed to Accrual, Study Active
To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas.
Are you Eligible? (Inclusion Criteria)
- Patients must be >= 18 years of age.
- Patients with advanced refractory cancers/lymphomas
Bladder Cancer , Brain and Spinal Tumors, Breast Cancer, Cervical Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Lung cancer, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Sarcomas (Bone and Soft Tissue), Testicular Cancer, Thyroid Cancer, Precision Oncology
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032